CD274 and angiosarcoma: Only a few angiosarcoma patients were evaluated in these studies, and the discrepancies and variabilities in the PD-L1 assay made it difficult to determine PD-L1 expression as a prognostic biomarker, especially for the subset of angiosarcoma patients.